SeoulMarkets · tag
dart
10 stories tagged “dart”, each from official Korean data with its source and timestamp.
A 75-point stake vanished — and the filing didn't name who took over
Tongyang Life's Chinese owner reported selling its entire stake in one filing, the largest exit in our ledger of Korean ownership disclosures. Of the nine biggest full sell-outs we found, only three say a controlling shareholder changed.
Samsung Life's rumor answer: not confirmed, not denied
A news report said Samsung Fire and Samsung Life were buying large UK and US insurers. Samsung Life's own DART filing says only that it is reviewing investment targets — nothing decided. It has until October 2 to say more.
96% of Korean firms pay men more
A census of 2,282 Korean listed companies' own half-year filings: the median company pays men 35.9% more than women. 96.0% pay men more by 5% or more. Only 1.4% pay women more.
Korea's listed firms: median tenure is 6.2 years
A census of 2,839 Korean listed companies' own annual filings: the median company's staff has stayed 6.2 years on average. 1 in 8 companies average under 3 years — and a smaller 1 in 17 average 15 years or more.
From Celltrion to KG Mobility, one flaw repeats
This week we ranked 35 Korean capital-raising filings three ways — buybacks, rights issues, convertible bonds. In every single one, the size of the deal did not predict what it meant for existing shareholders.
KG Mobility's convertible bond dilutes shares 22%
Five Korean convertible bonds filed this week all pay 0% surface interest — the option to convert is the entire return. Potential dilution on conversion ranges from 1.0% to 22.0%, and it isn't the biggest raise that dilutes least.
Meritz Securities: top pay, 2.18x gender gap
CEOScore reported nine Korean firms with H1 2026 average pay above ₩100m. We re-pulled the same DART filings and split them by gender — every one has a gap, from 1.31x to 2.18x.
Celltrion's biggest buyback won't cancel a share
Celltrion's ₩100.0bn buyback dwarfs eight others filed with Korea's regulator this week — and carries no cancellation clause. The three firms that do promise to cancel are the smallest on the list.
Samsung Biologics raised 300x more, diluted 11x less
Samsung Biologics' ₩3.00tn rights issue diluted shareholders 4.7%. PhionX raised 300 times less — and diluted 53.8%, eleven times more. Twenty-one filings this week show size doesn't predict dilution.
Why the Korean market numbers you can legally read are always a day old
The data this site publishes settles on a one-business-day lag — not by editorial choice but because that is what the redistributable sources release. One exception changes what is possible.